NCCN
No single point mutations that are contraindicated
What is Iclusig
44% at 12 months
What is Optic response with or without the T315i Mutation
Peripheral Neuropath (Ninlaro, Iclusig or Both)
What is Both
___ can be used in place of _____ and _____ when experiencing tolerability or logistical barriers
What is Ninlaro, Velcade and Kyprolis
5.8 Month PFS
What is Remix 4L Therapy
Gastrointestinal Toxicity (Ninlaro, Iclusig or Both)
What is Ninlaro
NCCN guidelines had 5 revisions in the past 12 months 2 of which included changes to
What is Ninlaro
64% by 60 months
What is Optic 5 year with T315i Mutations
Hepatotoxicity (Ninlaro, Iclusig or Both)
What is Both
NCCN recommends use in this line of therapy but FDA guidelines do not.
What is Ninlaro in the maintenance setting
21.4 Month PFS
What is Patients with High Risk factors Tourmaline MM1
In Optic 5 year of the 6 patients the experienced a grade 3/4 TE-AOE how many were beyond 2 years of therapy
What is 1 patient
Contraindicated for M244V and possiblely for A337T and P465S
What is Asciminib
All of the patients during a 12 month period vs patients only at a period 12 months after the start.
What is by 12 months vs at 12 months
Death
What is a grade 5 TEAE